According to the research of Albert Ko at the Yale School of Medicine, leptospirosis makes a surprisingly high and previously unmeasured contribution to the global burden of disease. Ko’s team found that the tropical disease results in more than 60,000
Thirty years after the discovery of the HIV virus, researchers are still unable to find a cure for the disease. Kathryn Miller-Jensen at the Yale School of Engineering and Applied Science discusses the ability of latent HIV to reactivate, which is one of the properties of the virus that make it so difficult to treat.
Scientists are working towards better methods of drug delivery for diseases that attack the brain.
An organ transplant comes with a slew of complications, but perhaps the problem most overlooked is preserving the tissue once it is removed from the donor. Current means of storing intestines before they are transplanted involve simply a container filled
Mosquitoes Resistant to Malaria: Scientists investigate the innate immune response in Anopheles gambiae
Anopheles gambiae is professor Richard Baxter’s insect of interest, and it is easy to see why: The mosquito species found in sub-Saharan Africa excels at transmitting malaria, one of the deadliest infectious diseases. “[Malaria] is a scourge of the developing
Some of the world’s deadliest diseases manifest when the body begins to betray itself. In cancer, mutated cells proliferate and overrun normal ones. Lupus, an autoimmune disease, occurs when the body’s immune system begins to attack its own cells. But
Yale researchers led by professor David Spiegel have developed ARMs, a new class of chemicals that can be used to treat prostate cancer and other diseases.
Contrary to common scientific belief, proteins need not be large to have powerful biological functions.
East Meets West in Cancer Treatment: Ancient herbal remedies prove their worth in modern clinical trials
A Yale professor brings an ancient remedy to the forefront, showing that traditional herbs can combat cancer.
The Crews lab at Yale has developed variations on a class of proteins called PROTACs, which destroy rogue proteins within cancerous cells. Craig Crews has even created a company to bridge the gap between research and the real world.